Physician profile
Omar Meer
NPI 1699824474
$15,391.94
in general payments reported to CMS, 2019-2025
66 companies · $1,921 in 2025
The $1,921 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $4,441 · 2021: $1,434 · 2022: $2,060 · 2023: $2,095 · 2024: $1,863 · 2025: $1,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,879.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,201.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,510.22 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $780.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $704.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $697.97 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Incyte Corporation | $658.86 | 2019-2025 | Jakafi |
| Rigel Pharmaceuticals, INC. | $621.20 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Janssen Pharmaceuticals, INC | $443.40 | 2019-2024 | Xarelto |
| Janssen Biotech, INC. | $329.71 | 2019-2025 | Talvey, Imbruvica, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $326.87 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $313.88 | 2019-2022 | |
| Epizyme, INC. | $291.02 | 2020-2022 | |
| Esperion Therapeutics, INC. | $267.25 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.19 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $255.65 | 2019-2023 | Repatha, Otezla |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Meer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.